Dear Illumina Stock Fans, Mark Your Calendars for September 21
If you hold Illumina (ILMN) stock, circle Sept. 21 on your calendar. That is the day Illumina officially joins the S&P 500 ($SPX), one of the most closely followed stock indices in the world.
S&P Dow Jones Indices announced the index rebalancing change on Friday. Illumina will be added to the benchmark alongside Bloom Energy (BE) and Everpure (P). The three companies are replacing Molson Coors Beverage (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR).
For Illumina investors, the S&P 500 index inclusion is a milestone worth noting. Valued at a market cap of $33 billion, ILMN stock has returned 112% over the last 12 months. However, ILMN stock has grossly underperformed the S&P 500 index over the past decade, returning just 16%.
Why Joining the S&P 500 Index Matters
Passive investing has gained massive traction over the last 15 years. Millions of investors have a sizable exposure to passively managed funds that track popular indices such as the S&P 500. When a company joins an index, these funds must buy shares to stay aligned with the benchmark, which can create a wave of short-term buying pressure.
There's another layer to this story too. According to the index change data, Illumina is leaving the S&P MidCap 400 to move into the S&P 500. Moving from mid-cap to large-cap status signals that a company has grown significantly and matured as a business, which is the case for Illumina.
Illumina Stock Price and Recent Momentum
Illumina, based in San Diego, makes sequencing and array-based instruments used for genetic and genomic analysis. Its customers range from hospitals and research centers to pharmaceutical and biotech companies.
In Q2 of 2026, Illumina reported revenue of $1.16 billion, an increase of 9.5% year-over-year (YoY). CEO Jacob Thaysen called it the fastest revenue growth since he joined the company. Rest of World organic revenue grew 8.1%, above the high end of guidance. Earnings per share rose about 10% YoY to $1.31.
CFO Ankur Dhingra said the company placed more than 95 NovaSeq X instruments during the quarter, part of a stretch of stronger-than-expected demand from clinical customers. As of Q2, roughly 78% of clinical sequencing volume had already shifted onto the NovaSeq X platform.
Clinical markets, which make up around 65% of Illumina's sequencing consumables revenue, remain the biggest driver. Executives said clinical consumables growth is now tracking toward the mid-teens for the year, up from earlier estimates, with the U.S. and Canada region growing above 20%.
Beyond core sequencing, Illumina is pushing into what it calls multiomics. This summer the company launched StrataMap Spatial, a new spatial biology workflow, and continues to see momentum from its SomaLogic acquisition through the SomaScan and SomaSeq product lines.
The company is also building out BioInsight, a data- and AI-focused initiative that includes the Billion Cell Atlas, a large-scale perturbation data set for biopharma customers. Illumina has delivered over 300 million cells so far and added three new pharma partners after quarter-end, bringing its total to six. Illumina also strengthened its leadership this quarter, welcoming Michael Sullivan and Julie Coletti to management, plus David King and Dan Skovronsky to its board.
Given the strong first half, Illumina raised its full-year 2026 guidance. The company now expects reported revenue between $4.60 billion and $4.64 billion, along with earnings per share of $5.30 to $5.40, up from prior estimates. Third quarter guidance calls for revenue between $1.14 billion and $1.16 billion, with earnings per share of $1.33 to $1.38.
What to Watch Next for ILMN Stock
Investors tracking the stock will want to watch consumables growth as newly placed instruments start generating regular usage, which management expects to build steadily through the second half of the year and into 2027.
Executives also pointed to early traction in BioInsight and continued expansion of the NovaSeq X installed base as reasons for confidence heading into next year. Combined with joining the S&P 500, it adds up to a notable stretch for a company that spent much of the last few years proving its turnaround story was real.
Analysts tracking ILMN stock forecast revenue to increase from $4.34 billion in 2025 to $6 billion in 2030. Over this period, free cash flow is projected to expand from $930 million to $1.68 billion.
Out of the 20 analysts covering ILMN stock, nine recommend “Strong Buy,” one recommends “Moderate Buy,” seven recommend “Hold,” one recommends “Moderate Sell,” and two recommend “Strong Sell.” The average Illumina stock price target is $207.21, below the current price of $218.
On the date of publication, Aditya Raghunath did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.